Trial intelligence / Profile preview

Bioequivalence study of Dapagliflozin 10 mg tablet vs Forxiga in healthy Thai volunteers under fasting

TCTR20250113001Phase 1Unknown

Sponsor
Bio-innova
Start
Feb 2025
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Status: unknown.

02

Drugs

dapagliflozin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on TCTR20250113001.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on TCTR20250113001.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call